In multivariate analyses adjusted for age and WBC, IC-AML with mutated ASXL1 (HR = 2.67, 95%CI = [1.15-6.24], p = 0.023) and UC-AML with mutated TP53 (HR = 5.44, 95%CI = [2.16-13.65], p < 0.001) had shorter OS than IC-AML with wild type ASXL1 (considered as reference, HR = 1). This evidence concerns the gene TP53 and acute myeloid leukemia.